ACR20 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	Weinblatt et al, 2003 (29)	4.63	2.47	8.66	45 / 67	9 / 62
Adalimumab	Keystone et al, 2004 (32)	2.46	1.87	3.22	122 / 207	48 / 200
Adalimumab		2.93	2.00	4.29		
Etanercept	Weinblatt et al, 1999 (25)	2.67	1.44	4.94	42 / 59	8 / 30
Etanercept		2.67	1.31	5.44		
Infliximab	Lipsky et al, 2000 (19)	2.46	1.45	4.15	36 / 86	15 / 88
Infliximab	Westhovens et al, 2006 (23)	2.31	1.88	2.83	199 / 360	87 / 363
Infliximab		2.35	1.66	3.32		
Overall		2.60	2.05	3.31		



ACR50 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Control
Adalimumab	Weinblatt et al, 2003 (29)	6.85	2.88	16.31	37 / 67	5 / 62
Adalimumab	Keystone et al, 2004 (32)	4.37	2.77	6.91	86 / 207	19 / 200
Adalimumab		4.82	3.22	7.22		
Etanercept	Weinblatt et al, 1999 (25)	11.69	1.66	82.47	23 / 59	1 / 30
Etanercept		11.69	1.66	82.47		
Infliximab	Lipsky et al, 2000 (19)	2.63	1.16	5.98	18 / 86	7 / 88
Infliximab	Westhovens et al, 2006 (23)	3.36	2.34	4.82	110 / 360	33 / 363
Infliximab		3.23	2.32	4.49		
Overall		4.13	2.59	6.59		



ACR70 response

Group by Anti-TNF	Study name	Statistics for each study: Risk ratio	Lower limit	Upper limit	Events / Total: Anti-TNFα	Group-B
Adalimumab	Weinblatt et al, 2003 (29)	5.55	1.72	17.93	18 / 67	3 / 62
Adalimumab	Keystone et al, 2004 (32)	5.15	2.60	10.22	48 / 207	9 / 200
Adalimumab		5.25	2.91	9.49		
Etanercept	Weinblatt et al, 1999 (25)	9.82	0.59	163.15	9 / 59	0 / 30
Etanercept		9.82	0.59	163.15		
Infliximab	Lipsky et al, 2000 (19)	4.60	1.02	20.70	9 / 86	2 / 88
Infliximab	Westhovens et al, 2006 (23)	3.02	1.75	5.23	48 / 360	16 / 363
Infliximab		3.18	1.90	5.31		
Overall		4.14	2.43	7.05